

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/876,997
				Filing Date	June 8, 2001
				First Named Inventor	J.-B. Dumas Milne Edwards
				Art Unit	1645 1652
				Examiner Name	unknown RAMIREZ
Sheet	1	of	3	Attorney Docket Number	G-078US04CIP

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ - Kind Code ⁵ (if known)			
DR	F1	EP	1130094 A2 (CD-ROM)	07/07/2000 *	Helix Research Institute	
DR	F2	WO	98/55814 A2	12/10/1998	Genetics Institute, Inc.	
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature	Delia Ramirez <i>DR</i>	Date Considered	8/18/03
--------------------	-------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/876,997	
			Filing Date	June 8, 2001	
			First Named Inventor	J.-B. Dumas Milne Edwards	
			Group Art Unit	1845 1652	
			Examiner Name	unknown RAMIREZ	
			Attorney Docket Number	G-078US04CIP	
Sheet	2	of	3		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
DR	R1	BOUGUELERET, L. <i>et al.</i> , "Extended cDNAs useful for expressing secreted proteins and to obtain specific antibodies", 2000, pp. 203-204, Accession No. AAY59685.			
	R2	CAMERON, C. <i>et al.</i> , "Function and Protective Capacity of <i>Treponema pallidum</i> subsp. <i>pallidum</i> Glycerophosphodiester Phosphodiesterase", <i>Infection and Immunity</i> (1998), pp. 5763-5770, Vol. 66, No. 12, American Society for Microbiology.			
	R3	DOWNES, G. <i>et al.</i> , "Structure and Mapping of the G Protein $\gamma 3$ Subunit Gene and a Divergently Transcribed Novel Gene, <i>Gng31g</i> ", <i>Genomics</i> (1998), pp. 220-230, Vol. 53, Academic Press.			
	R4	INOUE, S. <i>et al.</i> , "Growth Suppression of <i>Escherichia coli</i> by Induction of Expression of Mammalian Genes with Transmembrane or ATPase Domains", <i>Biochem. Biophys. Res. Comm.</i> (2000), pp. 553-561, Vol. 268, Academic Press.			
	R5	JANSON, H., <i>et al.</i> , "Protein D, the Glycerophosphodiester Phosphodiesterase from <i>Haemophilus influenzae</i> with Affinity for Human Immunoglobulin D, Influences Virulence in a Rat Otitis Model", <i>Infection and Immunity</i> , 1994, pp. 4848-4854, Vol. 62, No. 11, American Society for Microbiology.			
	R6	LARSON, Y., <i>et al.</i> , "Periplasmic Glycerophosphodiester Phosphodiesterase of <i>Escherichia coli</i> , a New Enzyme of the <i>glp</i> Regulon", <i>J. Biol. Chem.</i> , 1983, pp. 5428-5432, Vol. 258, No. 9.			
	R7	MAGRÉ, J. <i>et al.</i> , "Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13", <i>Nature Genetics</i> (2001), pp. 365-370, Vol. 28.			
	R8	MELDRUM, Brian, "Glutamate as a Neurotransmitter in the Brain: Review of Physiology and Pathology", <i>The Journal of Nutrition - Supplement</i> (presented at the International Symposium on Glutamate, 1998), 2000, pp. 1007S-1015S, Pub: American Society for Nutritional Sciences.			
	R9	MUNSON, R. <i>et al.</i> , "Protein D, a Putative Immunoglobulin D-Binding Protein Produced by <i>Haemophilus influenzae</i> , is Glycerophosphodiester Phosphodiesterase", <i>J. Bacteriology</i> , 1993, pp. 4569-4571, Vol. 175, No. 14.			
	R10	NEER, Eva, "Heterotrimeric G Proteins: Organizers of Transmembrane Signals", <i>Cell</i> , 1995, pp. 249-257, Vol. 80, Cell Press.			
	R11	SCHOEPP, D. <i>et al.</i> , "Metabotropic glutamate receptors in brain function and pathology", <i>TIPS</i> , 1993, pp. 13-20, Vol. 14, Elsevier Science Publishers, Ltd., UK.			
DR	R12	ZHENG, B. <i>et al.</i> , "MIR16, a putative membrane glycerophosphodiester phosphodiesterase, interacts with RGS16, <i>PNAS</i> , 2000, pp. 3999-4004, Vol. 97, No. 8.			

Examiner Signature	<i>Delia Ramirez</i>	Date Considered	8/18/03
--------------------	----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number	09/876,997
Filing Date	June 8, 2001
First Named Inventor	J.-B. Dumas Milne Edwards
Group Art Unit	1645 1652
Examiner Name	unknown RAMIREZ
Attorney Docket Number	G-078US04CIP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DR	R13	ZHENG, B. et al., "MIR16, a putative membrane glycerophosphodiester phosphodiesterase, interacts with RGS16, <i>Proc. Natl. Acad. Sci. U.S.A.</i> (2000), pp. 3999-4004, Vol. 97, No. 8, Accession No. AAF85234 (bases 1 to 331).	
	R14	ZHENG, B. et al., "MIR16, a putative membrane glycerophosphodiester phosphodiesterase, interacts with RGS16, <i>Proc. Natl. Acad. Sci. U.S.A.</i> (2000), pp. 3999-4004, Vol. 97, No. 8, Accession No. AF212862 (bases 1 to 1200).	
	R15	Glycerophosphoryl Diester Phosphodiesterase <i>Escherichia coli</i> (1989), NiceProt View of SWISS-PROT: P10908.	
	R16	Glycerophosphoryl Diester Phosphodiesterase, periplasmic [Precursor] <i>Escherichia coli</i> (1991), NiceProt View of SWISS-PROT: P09394.	
	R17	Glycerophosphoryl Diester Phosphodiesterase [Precursor] <i>Haemophilus Influenzae</i> (1995), NiceProt View of SWISS-PROT: Q06282.	
	R18	Similar to G Protein Gamma 3 Linked Gene <i>Homo Sapiens</i> (2001), NiceProt View of SWISS-PROT: Q9BSQ0.	
DR	R19	Hypothetical 43.1 kDa protein <i>Mus musculus</i> (2000), NiceProt View of SWISS-PROT: Q9JMF1.	
	R20		
	R21		
	R22		
	R23		
	R24		
	R25		

Examiner Signature	<i>DL Delia Ramirez</i>	Date Considered	8/18/03
--------------------	-------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.